USPTO Examiner HINES JANA A - Art Unit 1645

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18737799COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSJune 2024April 2025Abandon1020YesNo
18633805DIETARY SUPPLEMENT COMPOSITION FOR TREATING AND MANAGING ACNEApril 2024September 2024Allow510YesNo
18430254ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024March 2025Allow1420NoNo
18518117METHODS AND ARRAYS FOR TARGET ANALYTE DETECTION AND DETERMINATION OF TARGET ANALYTE CONCENTRATION IN SOLUTIONNovember 2023May 2025Abandon1820NoNo
18506072COMPOSITIONS AND METHODS FOR DETECTING PROTEASE ACTIVITY IN BIOLOGICAL SYSTEMSNovember 2023April 2025Abandon1710NoNo
18386555ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10- TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow301NoNo
18469188PHARMACEUTICAL COMPOSITION COMPRISING A PROBIOTIC AND PREBIOTIC TO PREVENT ACQUISITION OF OR TREAT DRUG RESISTANT INFECTIONSSeptember 2023April 2025Abandon1821YesNo
18217206FAST DIAGNOSIS AND PERSONALIZED TREATMENTS FOR ACNEJune 2023May 2025Abandon2311NoNo
18139626Anti-PfRH5 Antibodies and Antigen-Binding Fragments ThereofApril 2023May 2024Allow1300NoNo
18192505USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF A DISEASEMarch 2023November 2024Abandon2001NoNo
18182055COMPOSITIONS AND METHODS FOR THE INDUCTION OF CD8+ T-CELLSMarch 2023October 2024Allow2020YesNo
18149612PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIESJanuary 2023July 2024Abandon1810NoNo
18049993METHODS AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINSOctober 2022November 2024Abandon2511NoNo
17952761ASSAYS FOR DETERMINING THE PATHOGENCITY OF TOXOPLASMA INFECTIONSSeptember 2022February 2024Abandon1610NoNo
17934054ALPHA-HEMOLYSIN VARIANTS WITH ALTERED CHARACTERISTICSSeptember 2022March 2024Allow1811YesNo
17739553ANTI-MICROBIAL SEAWEED EXTRACTS, COMPOSITIONS AND USES THEREOFMay 2022January 2024Abandon2110NoNo
17662188PROBIOTIC COMPOSITIONS FOR PRODUCTION OF DOPAMINEMay 2022June 2025Allow3740YesNo
17711081PROBIOTICS FOR USE IN THE PREVENTION OR TREATMENT OF ILLNESS AND/OR SYMPTOMS ASSOCIATED WITH CORONAVIRUSESApril 2022September 2023Allow1710NoNo
17705619MHC CLASS I EPITOPE DELIVERING POLYPEPTIDESMarch 2022February 2024Allow2310NoNo
17702854COMPOSITIONS COMPRISING BACTERIAL STRAINSMarch 2022March 2024Abandon2410NoNo
17674932MENINGOCOCCAL B RECOMBINANT VACCINEFebruary 2022March 2024Allow2531YesNo
17591631DIAGNOSTIC METHOD EMPLOYING HNLFebruary 2022January 2024Abandon2311NoNo
17584956BACTERIA ENGINEERED TO TREAT METABOLIC DISEASESJanuary 2022September 2023Allow1910YesNo
17595998TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERSDecember 2021March 2025Allow3911NoNo
17534970METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROPHYLAXIS AND TREATMENT OF LYME DISEASENovember 2021March 2025Allow4051NoNo
17608242VAGINAL MICROBIOME MARKERS FOR PREDICTION OF PREVENTION OF PRETERM BIRTH AND OTHER ADVERSE PREGNANCY OUTCOMESNovember 2021April 2025Abandon4201NoNo
17508692TREATMENT OF STAPHYLOCOCCAL DISORDERSOctober 2021April 2024Allow2911NoNo
17498278METHODS FOR TREATING NEPHROTIC SYNDROMEOctober 2021August 2023Allow2210NoNo
17496926METHODS AND ARRAYS FOR TARGET ANALYTE DETECTION AND DETERMINATION OF TARGET ANALYTE CONCENTRATION IN SOLUTIONOctober 2021July 2023Allow2121YesNo
17600743METHOD FOR DETECTING OR MONITORING THE PROGRESSION OF A CHRONIC AUTOIMMUNE DISEASE BY IMMUNOASSAYOctober 2021May 2025Abandon4311NoNo
17481606FLUID HANDLING DEVICESeptember 2021October 2024Abandon3701NoNo
17460658NOVEL PNEUMOCOCCAL VACCINE FORMULATIONSAugust 2021December 2023Abandon2821YesNo
17410908BACTERIAL VACCINE COMPONENTS AND USES THEREOFAugust 2021December 2023Abandon2810NoNo
17403284DIRECT-FED MICROBIALSAugust 2021July 2023Allow2310NoNo
17400441ENGINEERED BOTULINUM NEUROTOXINAugust 2021November 2024Abandon3901NoNo
17397915ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTIONAugust 2021October 2023Allow2611NoNo
17419855BACTERIAL VACCINEJune 2021April 2025Allow4630NoNo
17358086BACTERIAL VACCINE COMPONENTS AND USES THEREOFJune 2021November 2023Abandon2910NoNo
17354161METHOD FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIAJune 2021September 2023Abandon2710NoNo
17417364NUCLEIC ACID DETECTIONJune 2021October 2024Abandon4010NoNo
17350690Methods And Compositions For Improved Production Of Fatty Acids And Derivatives ThereofJune 2021October 2024Abandon4010NoNo
17349627ACTIVE SUBSTANCE OF MORCHELLA, ITS USE AND A COMPOSITION THEREOF FOR IMPROVING THE REPRODUCTIVE FUNCTIONJune 2021May 2023Allow2320NoNo
17340532Compositions and Methods Related to Protein A (SpA) VariantsJune 2021November 2023Allow2910NoNo
17297385BIOSENSOR AND METHOD FOR DETECTION OF ANALYTESMay 2021June 2025Allow4911NoNo
17290385HAFNIA ALVEI FORMULATIONSApril 2021September 2024Abandon4010NoNo
17246167COMPOSITIONS AND METHODS FOR DETECTING PROTEASE ACTIVITY IN BIOLOGICAL SYSTEMSApril 2021August 2023Allow2710NoNo
17288909COMPOSITIONS AND METHODS FOR OCHROBACTRUM-MEDIATED PLANT TRANSFORMATIONApril 2021August 2024Abandon4001NoNo
17240433PROBIOTICS FOR USE IN THE PREVENTION OR TREATMENT OF ILLNESS AND/OR SYMPTOMS ASSOCIATED WITH CORONAVIRUSESApril 2021December 2021Allow821YesNo
17288308KITS AND METHODS FOR REAL-TIME MULITPLEX DETECTION AND IDENTIFICATION OF PATHOGENSApril 2021November 2023Abandon3010NoNo
17231526MHC CLASS I EPITOPE DELIVERING POLYPEPTIDESApril 2021December 2021Allow811NoNo
17228382DIAGNOSIS AND TREATMENT OF INVASIVE ASPERGILLOSISApril 2021February 2023Allow2210NoNo
17277592COMPOSITION AGAINST RESISTANT ORGANISMS (MRSA)March 2021November 2023Abandon3210NoNo
17200553COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENTMarch 2021April 2024Allow3711YesNo
17186366Vaccine AdjuvantFebruary 2021May 2024Allow3921NoNo
17178412COMPOSITIONS AND METHODS FOR TREATING AN INFLAMMATORY DISEASE OR DISORDERFebruary 2021July 2023Abandon2911NoNo
17268500RAPID DIAGNOSTICS OF MYCOBACTERIA WITH LECTIN CONJUGATED PARTICLESFebruary 2021November 2022Abandon2120NoNo
17268380METHOD AND COMPOSITION FOR STIMULATING IMMUNE RESPONSEFebruary 2021May 2024Abandon3911NoNo
17149227PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIESJanuary 2021October 2022Allow2100NoNo
17259457PREVENTING FUNGAL GROWTH IN HONEY BEE COLONIES AND RELATED MATERIALS AND METHODSJanuary 2021March 2023Abandon2610NoNo
17142792VIRB10 FOR VACCINATION AGAINST GRAM NEGATIVE BACTERIAJanuary 2021August 2024Allow4330YesNo
17116353METHODS FOR CONTROLLING PROTEASE PRODUCTIONDecember 2020February 2024Allow3840YesNo
17115827IMMUNIZATION WITH POLYVALENT VENOM VACCINESDecember 2020July 2022Allow1920NoNo
17059918BIOMARKERS FOR THE DIAGNOSIS OF INVASIVE FUNGAL INFECTIONSNovember 2020August 2024Allow4520YesNo
17093133MODIFIED BACTERIA HAVING IMPROVED PHARMACOKINETICS AND TUMOR COLONIZATION ENHANCING ANTITUMOR ACTIVITYNovember 2020June 2023Allow3211YesNo
17053232Methods and Compositions for Treating or Preventing Gut Barrier DysfunctionNovember 2020January 2023Abandon2710NoNo
17051653PROBIOTIC BIFIDOBACTERIUM BREVE STRAIN AND COMPOSITIONS COMPRISING SAID STRAINOctober 2020January 2023Allow2610YesNo
17050666Non-integrative Listeria-based vaccine and method for inducing antitumor immune responseOctober 2020February 2023Allow2811NoNo
17073006USES OF PARASITE MACROPHAGE MIGRATION INHIBITORY FACTORSOctober 2020November 2022Abandon2510NoNo
17071425HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSOctober 2020September 2022Allow2311YesNo
17045315Therapeutic Microvesicles of Probiotic BacteriaOctober 2020August 2023Allow3411YesNo
17061155Antigenic OspA PolypeptidesOctober 2020January 2024Allow4021YesNo
17033034FAST DIAGNOSIS AND PERSONALIZED TREATMENTS FOR ACNESeptember 2020December 2022Allow2611YesNo
17041603SENSOR FOR INDICATING A POTENTIAL FORTHCOMING SKIN OR GASTROINTESTINAL ISSUE AND METHODS OF USING THE SAMESeptember 2020February 2024Abandon4131NoYes
17041595Anti-PfRH5 Antibodies and Antigen-Binding Fragments ThereofSeptember 2020January 2023Allow2821YesNo
16982322A METHOD FOR LYOPHILIZING LIVE VACCINE STRAINS OF FRANCISELLA TULARENSISSeptember 2020April 2023Allow3131YesNo
17019596COMPOSITIONS COMPRISING BACTERIAL STRAINS AND USE THEREOF IN CONTROLLING PATHOGENIC MICROORGANISMSSeptember 2020October 2022Allow2511NoNo
17020658METHODS FOR DETECTION OF BOTULINUM NEUROTOXINSeptember 2020September 2022Allow2411NoNo
17019645ASSAYS FOR DETERMINIG THE PATHOGENCITY OF TOXOPLASMA INFECTIONSSeptember 2020October 2022Abandon2510NoNo
16979459COMPOSITIONS FOR USE IN BALANCING MICROBIOMESeptember 2020February 2025Abandon5361YesNo
17009108Lanthanide-Doped Nanoparticle Compositions for Detecting MicroorganismsSeptember 2020September 2024Abandon4820NoNo
17008282COMPOSITIONS AND METHODS FOR CHARACTERIZING AND DIAGNOSING PERIODONTAL DISEASEAugust 2020March 2023Allow3021YesNo
17006356COMPOSITIONS COMPRISING BACTERIAL STRAINSAugust 2020December 2021Allow1610NoNo
16999193AUTOMATED BIOREACTOR WITH FOAM COLLECTORAugust 2020July 2024Allow4721YesNo
16965657APPARATUS FOR SCREENING AND DIAGNOSIS OF MENINGITISJuly 2020March 2024Abandon4310NoNo
16940149VAGINITIS PATHOGEN-INHIBITING COMPOSITION, VAGINA-CLEANING COMPOSITION, AND USES THEREOFJuly 2020January 2023Abandon2920NoNo
16934888ELISA KIT FOR CLOSTRIDIUM NOVYI TYPE BJuly 2020June 2022Abandon2301NoNo
16959891A NOVEL LACTIC ACID BACTERIA AND ITS APPLICATIONSJuly 2020November 2023Allow4121YesNo
16916273SPECIES SPECIFIC ANTIGEN SEQUENCES FOR TICK-BORNE RELAPSING FEVER (TBRF) AND METHODS OF USEJune 2020March 2022Allow2110YesNo
16913857COCCIDIOSIS VACCINEJune 2020April 2022Allow2211NoNo
16902732HAFNIA ALVEI IMPACT ON REGULATION OF APPETITE AND METABOLIC SYNDROME ASPECTSJune 2020February 2022Allow2010NoNo
16901175O-Mannosyltransferase Deficient Filamentous Fungal Cells and Methods of Use ThereofJune 2020April 2022Abandon2210NoNo
16771979DEFINED THERAPEUTIC MICROBIOTA AND METHODS OF USE THEREOFJune 2020January 2023Allow3230YesNo
16880243TREATMENT OF INFLAMMATORY SKIN DISORDERSMay 2020December 2022Allow3120NoNo
15929741Methods and Compositions Related to Immunizing Against Staphylococcal Lung Diseases and ConditionsMay 2020December 2022Allow3111NoNo
16763902RAPID SELECTIVE DETECTION OF BACTERIAMay 2020October 2022Allow3011NoNo
16867891ALPHA-HEMOLYSIN VARIANTS WITH ALTERED CHARACTERISTICSMay 2020June 2022Allow2621YesNo
16864996PATHOGEN EFFECTORS FOR EARLY DETECTION OF CITRUS GREENING DISEASEMay 2020March 2023Abandon3401NoNo
16760432OSTRICH ANTIBODY FOR BACTERIAL INFECTIOUS DISEASESApril 2020August 2024Abandon5161YesNo
16760021BACTERIAL AND CELL COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER AND METHODS FOR ASSESSING A PROGNOSIS FOR PATIENTS HAVING THE SAMEApril 2020December 2024Allow5661YesNo
16759212METHODS AND COMPOSITIONS FOR IMPROVING ENGINEERED MICROBES THAT FIX NITROGENApril 2020March 2024Allow4711YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HINES, JANA A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
17
Examiner Affirmed
10
(58.8%)
Examiner Reversed
7
(41.2%)
Reversal Percentile
62.9%
Higher than average

What This Means

With a 41.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
118
Allowed After Appeal Filing
20
(16.9%)
Not Allowed After Appeal Filing
98
(83.1%)
Filing Benefit Percentile
18.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HINES, JANA A - Prosecution Strategy Guide

Executive Summary

Examiner HINES, JANA A works in Art Unit 1645 and has examined 823 patent applications in our dataset. With an allowance rate of 48.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner HINES, JANA A's allowance rate of 48.6% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HINES, JANA A receive 2.37 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HINES, JANA A is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.6% benefit to allowance rate for applications examined by HINES, JANA A. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.0% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 26.0% of cases where such amendments are filed. This entry rate is in the 27% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 74.6% of appeals filed. This is in the 59% percentile among all examiners. Of these withdrawals, 66.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 77.1% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.8% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.